 Edward Gardner
Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 43 | 2021 | 2454 | 3.790 |
Why?
| | Anti-HIV Agents | 22 | 2020 | 662 | 2.420 |
Why?
| | Medication Adherence | 15 | 2019 | 554 | 1.920 |
Why?
| | HIV Protease Inhibitors | 5 | 2019 | 64 | 1.730 |
Why?
| | Anti-Retroviral Agents | 5 | 2021 | 207 | 1.660 |
Why?
| | HIV-1 | 11 | 2021 | 772 | 1.530 |
Why?
| | Viral Load | 10 | 2019 | 406 | 1.260 |
Why?
| | Antiretroviral Therapy, Highly Active | 7 | 2017 | 258 | 1.110 |
Why?
| | Continuity of Patient Care | 3 | 2021 | 262 | 1.020 |
Why?
| | HIV Integrase Inhibitors | 2 | 2019 | 60 | 1.010 |
Why?
| | Adenine | 9 | 2020 | 222 | 0.930 |
Why?
| | Patient Compliance | 5 | 2017 | 532 | 0.880 |
Why?
| | Drug Resistance, Viral | 5 | 2011 | 98 | 0.870 |
Why?
| | Tenofovir | 9 | 2020 | 200 | 0.810 |
Why?
| | Organophosphates | 6 | 2020 | 90 | 0.680 |
Why?
| | Darunavir | 1 | 2019 | 17 | 0.680 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 28 | 0.670 |
Why?
| | Emtricitabine | 8 | 2019 | 146 | 0.650 |
Why?
| | Antiviral Agents | 5 | 2021 | 653 | 0.590 |
Why?
| | Healthcare Disparities | 1 | 2021 | 494 | 0.540 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2015 | 219 | 0.480 |
Why?
| | Health Services Administration | 1 | 2013 | 8 | 0.480 |
Why?
| | Public Health Administration | 1 | 2013 | 77 | 0.440 |
Why?
| | HIV | 4 | 2021 | 209 | 0.440 |
Why?
| | Adult | 40 | 2023 | 31324 | 0.410 |
Why?
| | Pyrrolidinones | 1 | 2011 | 25 | 0.410 |
Why?
| | CD4 Lymphocyte Count | 7 | 2019 | 261 | 0.410 |
Why?
| | Mass Screening | 5 | 2023 | 1048 | 0.400 |
Why?
| | Drug Therapy, Combination | 7 | 2021 | 964 | 0.400 |
Why?
| | Emergency Service, Hospital | 5 | 2023 | 1848 | 0.390 |
Why?
| | Male | 45 | 2023 | 57474 | 0.390 |
Why?
| | Humans | 61 | 2023 | 118251 | 0.390 |
Why?
| | Hepatitis C | 3 | 2023 | 217 | 0.390 |
Why?
| | Reverse Transcriptase Inhibitors | 2 | 2008 | 80 | 0.380 |
Why?
| | Middle Aged | 33 | 2023 | 27510 | 0.380 |
Why?
| | Dried Blood Spot Testing | 4 | 2019 | 68 | 0.380 |
Why?
| | Current Procedural Terminology | 1 | 2010 | 11 | 0.370 |
Why?
| | Fees and Charges | 1 | 2010 | 10 | 0.370 |
Why?
| | Female | 44 | 2023 | 61261 | 0.370 |
Why?
| | Patient Education as Topic | 3 | 2016 | 696 | 0.370 |
Why?
| | Online Systems | 1 | 2009 | 25 | 0.360 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2010 | 79 | 0.350 |
Why?
| | Antibodies, Neutralizing | 2 | 2021 | 225 | 0.350 |
Why?
| | Fibromyalgia | 1 | 2009 | 56 | 0.340 |
Why?
| | Drug Overdose | 3 | 2019 | 293 | 0.340 |
Why?
| | Rheumatology | 1 | 2010 | 87 | 0.340 |
Why?
| | Delivery of Health Care | 3 | 2014 | 862 | 0.330 |
Why?
| | Clostridium butyricum | 1 | 2008 | 2 | 0.320 |
Why?
| | Organophosphonates | 3 | 2015 | 94 | 0.320 |
Why?
| | Deoxycytidine | 3 | 2015 | 136 | 0.310 |
Why?
| | Naloxone | 3 | 2018 | 98 | 0.300 |
Why?
| | Clostridium Infections | 1 | 2008 | 57 | 0.300 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2009 | 228 | 0.300 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 665 | 0.290 |
Why?
| | Narcotic Antagonists | 3 | 2018 | 136 | 0.290 |
Why?
| | Analgesics, Opioid | 4 | 2019 | 789 | 0.280 |
Why?
| | Treatment Outcome | 10 | 2023 | 9319 | 0.270 |
Why?
| | Kartagener Syndrome | 1 | 2005 | 25 | 0.270 |
Why?
| | Health Care Costs | 2 | 2011 | 390 | 0.260 |
Why?
| | Molecular Epidemiology | 1 | 2005 | 69 | 0.260 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2005 | 63 | 0.260 |
Why?
| | Prospective Studies | 12 | 2023 | 6443 | 0.260 |
Why?
| | Macrolides | 1 | 2005 | 57 | 0.260 |
Why?
| | Patient Acceptance of Health Care | 1 | 2011 | 683 | 0.260 |
Why?
| | Lymphocyte Activation | 3 | 2021 | 1062 | 0.260 |
Why?
| | Blood Chemical Analysis | 3 | 2014 | 94 | 0.260 |
Why?
| | Adenosine Monophosphate | 2 | 2021 | 51 | 0.250 |
Why?
| | Alanine | 2 | 2021 | 102 | 0.250 |
Why?
| | Pre-Exposure Prophylaxis | 3 | 2017 | 173 | 0.250 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2005 | 62 | 0.250 |
Why?
| | Desiccation | 2 | 2014 | 17 | 0.240 |
Why?
| | Raltegravir Potassium | 2 | 2015 | 16 | 0.240 |
Why?
| | Abnormalities, Multiple | 1 | 2005 | 182 | 0.230 |
Why?
| | Hepacivirus | 3 | 2023 | 230 | 0.220 |
Why?
| | Retrospective Studies | 10 | 2021 | 12929 | 0.220 |
Why?
| | Specimen Handling | 2 | 2014 | 163 | 0.220 |
Why?
| | Sepsis | 1 | 2008 | 531 | 0.210 |
Why?
| | Cohort Studies | 5 | 2023 | 5078 | 0.200 |
Why?
| | Respiratory Tract Infections | 1 | 2005 | 329 | 0.200 |
Why?
| | Viremia | 2 | 2019 | 127 | 0.200 |
Why?
| | Arthritis, Rheumatoid | 1 | 2009 | 990 | 0.200 |
Why?
| | Substance-Related Disorders | 2 | 2018 | 967 | 0.190 |
Why?
| | Vaccines, Conjugate | 1 | 2021 | 63 | 0.190 |
Why?
| | Sexual and Gender Minorities | 2 | 2020 | 136 | 0.190 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2021 | 113 | 0.190 |
Why?
| | Research Subjects | 1 | 2020 | 40 | 0.180 |
Why?
| | Pneumococcal Infections | 1 | 2021 | 96 | 0.180 |
Why?
| | Internship and Residency | 1 | 2010 | 1005 | 0.180 |
Why?
| | Time-to-Treatment | 1 | 2021 | 148 | 0.180 |
Why?
| | Adaptive Immunity | 1 | 2021 | 160 | 0.180 |
Why?
| | Streptococcus pneumoniae | 1 | 2021 | 141 | 0.180 |
Why?
| | Gender Identity | 1 | 2020 | 102 | 0.180 |
Why?
| | Pneumococcal Vaccines | 1 | 2021 | 140 | 0.180 |
Why?
| | Sustained Virologic Response | 1 | 2019 | 33 | 0.170 |
Why?
| | RNA, Viral | 3 | 2021 | 568 | 0.170 |
Why?
| | Oxazines | 1 | 2019 | 25 | 0.170 |
Why?
| | Leukocytes, Mononuclear | 3 | 2016 | 504 | 0.170 |
Why?
| | Colorado | 5 | 2018 | 4178 | 0.170 |
Why?
| | Rectum | 2 | 2016 | 155 | 0.160 |
Why?
| | Directly Observed Therapy | 1 | 2017 | 14 | 0.160 |
Why?
| | Pyridones | 1 | 2019 | 119 | 0.160 |
Why?
| | Terminology as Topic | 1 | 2019 | 199 | 0.150 |
Why?
| | Atazanavir Sulfate | 2 | 2015 | 41 | 0.150 |
Why?
| | Drug Administration Schedule | 4 | 2018 | 734 | 0.150 |
Why?
| | B-Lymphocytes | 2 | 2021 | 767 | 0.150 |
Why?
| | Homosexuality, Male | 2 | 2016 | 165 | 0.150 |
Why?
| | Genitalia | 1 | 2016 | 27 | 0.140 |
Why?
| | Chronic Pain | 2 | 2018 | 211 | 0.140 |
Why?
| | Piperazines | 1 | 2019 | 316 | 0.140 |
Why?
| | Secondary Prevention | 1 | 2017 | 227 | 0.130 |
Why?
| | Mental Health Services | 1 | 2019 | 331 | 0.130 |
Why?
| | Coinfection | 1 | 2016 | 119 | 0.130 |
Why?
| | Genitalia, Female | 1 | 2015 | 40 | 0.130 |
Why?
| | Time Factors | 4 | 2016 | 6368 | 0.130 |
Why?
| | Biomarkers | 6 | 2021 | 3567 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 817 | 0.120 |
Why?
| | Disease Transmission, Infectious | 1 | 2014 | 56 | 0.120 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 21 | 0.120 |
Why?
| | Young Adult | 9 | 2021 | 10731 | 0.110 |
Why?
| | Immunologic Factors | 1 | 2015 | 224 | 0.110 |
Why?
| | Vaccination | 1 | 2021 | 1218 | 0.110 |
Why?
| | Cost-Benefit Analysis | 1 | 2015 | 551 | 0.110 |
Why?
| | Quality of Life | 2 | 2017 | 2355 | 0.110 |
Why?
| | Lamivudine | 1 | 2012 | 59 | 0.100 |
Why?
| | Zidovudine | 1 | 2012 | 77 | 0.100 |
Why?
| | Mental Disorders | 1 | 2019 | 935 | 0.100 |
Why?
| | Population Surveillance | 1 | 2014 | 413 | 0.100 |
Why?
| | Intention to Treat Analysis | 2 | 2021 | 70 | 0.100 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2010 | 13 | 0.100 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1770 | 0.090 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 29 | 0.090 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1121 | 0.090 |
Why?
| | Treatment Failure | 2 | 2021 | 340 | 0.090 |
Why?
| | Chromatography, Liquid | 3 | 2019 | 353 | 0.090 |
Why?
| | Case-Control Studies | 3 | 2021 | 3156 | 0.090 |
Why?
| | Risk Factors | 4 | 2021 | 8958 | 0.090 |
Why?
| | United States | 3 | 2021 | 12488 | 0.090 |
Why?
| | Adolescent | 8 | 2021 | 18364 | 0.090 |
Why?
| | alpha 1-Antitrypsin | 1 | 2010 | 111 | 0.090 |
Why?
| | Tandem Mass Spectrometry | 3 | 2019 | 418 | 0.090 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2009 | 60 | 0.090 |
Why?
| | Public Health | 1 | 2013 | 447 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1183 | 0.080 |
Why?
| | Comprehension | 1 | 2009 | 162 | 0.080 |
Why?
| | Cost Savings | 1 | 2008 | 77 | 0.080 |
Why?
| | Oligopeptides | 1 | 2009 | 250 | 0.080 |
Why?
| | Educational Status | 1 | 2009 | 437 | 0.080 |
Why?
| | Disease Progression | 2 | 2023 | 2477 | 0.080 |
Why?
| | Anti-Bacterial Agents | 2 | 2008 | 1514 | 0.070 |
Why?
| | Drug Costs | 1 | 2008 | 93 | 0.070 |
Why?
| | Double-Blind Method | 2 | 2021 | 1683 | 0.070 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 80 | 0.070 |
Why?
| | Catheterization, Central Venous | 1 | 2008 | 95 | 0.070 |
Why?
| | Osteomyelitis | 1 | 2008 | 109 | 0.070 |
Why?
| | Aged | 6 | 2021 | 19594 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2010 | 526 | 0.070 |
Why?
| | Pyridines | 1 | 2009 | 436 | 0.070 |
Why?
| | Axonemal Dyneins | 1 | 2005 | 8 | 0.070 |
Why?
| | Inflammation | 1 | 2016 | 2545 | 0.070 |
Why?
| | HSP40 Heat-Shock Proteins | 1 | 2005 | 21 | 0.070 |
Why?
| | Dyneins | 1 | 2005 | 30 | 0.070 |
Why?
| | Nonlinear Dynamics | 1 | 2005 | 88 | 0.060 |
Why?
| | Pilot Projects | 1 | 2009 | 1405 | 0.060 |
Why?
| | Mycobacterium avium Complex | 1 | 2005 | 92 | 0.060 |
Why?
| | Nasal Mucosa | 1 | 2005 | 97 | 0.060 |
Why?
| | Half-Life | 2 | 2016 | 147 | 0.060 |
Why?
| | Heat-Shock Proteins | 1 | 2005 | 128 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2008 | 1288 | 0.060 |
Why?
| | Genetic Linkage | 1 | 2005 | 321 | 0.060 |
Why?
| | Bronchiectasis | 1 | 2005 | 105 | 0.060 |
Why?
| | Gene Expression | 1 | 2009 | 1482 | 0.060 |
Why?
| | Genotype | 1 | 2009 | 1870 | 0.060 |
Why?
| | Staphylococcal Infections | 1 | 2008 | 348 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 1237 | 0.060 |
Why?
| | Curriculum | 1 | 2010 | 908 | 0.060 |
Why?
| | Spleen | 1 | 2005 | 504 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1787 | 0.060 |
Why?
| | Logistic Models | 1 | 2008 | 1896 | 0.050 |
Why?
| | Multivariate Analysis | 1 | 2006 | 1469 | 0.050 |
Why?
| | Primary Health Care | 3 | 2018 | 1539 | 0.050 |
Why?
| | Recurrence | 1 | 2005 | 971 | 0.050 |
Why?
| | Hospitalization | 2 | 2021 | 1778 | 0.050 |
Why?
| | Medical Futility | 1 | 2021 | 22 | 0.050 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 1 | 2021 | 9 | 0.050 |
Why?
| | Fatigue | 1 | 2023 | 293 | 0.050 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 26 | 0.050 |
Why?
| | Qualitative Research | 2 | 2016 | 952 | 0.050 |
Why?
| | Ultrasonography | 1 | 2005 | 714 | 0.050 |
Why?
| | Antigens, Viral | 1 | 2021 | 178 | 0.050 |
Why?
| | Mutation | 1 | 2011 | 3435 | 0.050 |
Why?
| | Antibodies, Bacterial | 1 | 2021 | 124 | 0.050 |
Why?
| | Transsexualism | 1 | 2020 | 17 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2006 | 776 | 0.040 |
Why?
| | Plasma | 2 | 2012 | 194 | 0.040 |
Why?
| | Attitude of Health Personnel | 2 | 2016 | 990 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2019 | 78 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2008 | 4574 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2019 | 167 | 0.040 |
Why?
| | Odds Ratio | 1 | 2021 | 993 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2019 | 121 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2018 | 276 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2016 | 2491 | 0.040 |
Why?
| | Liver | 1 | 2005 | 1803 | 0.040 |
Why?
| | Cell Communication | 1 | 2018 | 279 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2020 | 545 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2017 | 456 | 0.030 |
Why?
| | Spermatozoa | 1 | 2016 | 91 | 0.030 |
Why?
| | Ribavirin | 1 | 2016 | 88 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2005 | 2433 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2019 | 685 | 0.030 |
Why?
| | Health Status | 1 | 2020 | 723 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 4521 | 0.030 |
Why?
| | Blood | 1 | 2015 | 97 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1516 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1857 | 0.030 |
Why?
| | Hepatitis C, Chronic | 1 | 2016 | 151 | 0.030 |
Why?
| | Mental Health | 1 | 2019 | 566 | 0.030 |
Why?
| | Focus Groups | 1 | 2015 | 387 | 0.030 |
Why?
| | Models, Statistical | 1 | 2018 | 633 | 0.030 |
Why?
| | Risk | 1 | 2016 | 849 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2015 | 248 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 393 | 0.030 |
Why?
| | Physicians, Primary Care | 1 | 2015 | 220 | 0.030 |
Why?
| | Self Report | 1 | 2016 | 698 | 0.030 |
Why?
| | Dideoxynucleotides | 1 | 2012 | 14 | 0.030 |
Why?
| | Cytidine Triphosphate | 1 | 2012 | 15 | 0.030 |
Why?
| | Thymine Nucleotides | 1 | 2012 | 15 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2855 | 0.020 |
Why?
| | Food-Drug Interactions | 1 | 2010 | 6 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2018 | 809 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2016 | 951 | 0.020 |
Why?
| | Chemoprevention | 1 | 2010 | 89 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 99 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2010 | 222 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3424 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2010 | 286 | 0.020 |
Why?
| | Prednisone | 1 | 2010 | 235 | 0.020 |
Why?
| | Drug Interactions | 1 | 2010 | 351 | 0.020 |
Why?
| | Doxorubicin | 1 | 2010 | 301 | 0.020 |
Why?
| | Ritonavir | 1 | 2009 | 70 | 0.020 |
Why?
| | Clinical Competence | 1 | 2015 | 950 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3043 | 0.020 |
Why?
| | Haplotypes | 1 | 2009 | 474 | 0.020 |
Why?
| | Erythrocytes | 1 | 2012 | 619 | 0.020 |
Why?
| | Animals | 1 | 2009 | 33152 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 6541 | 0.020 |
Why?
| | Sex Factors | 1 | 2012 | 1765 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2009 | 748 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 641 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4684 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2009 | 2855 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1385 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2008 | 2659 | 0.010 |
Why?
|
|
Gardner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|